The global Nuclear Medicine Software Market is experiencing significant growth, with its value increasing from US$887.5 million in 2024 to US$970.0 million in 2025. Projections suggest a robust compound annual growth rate (CAGR) of 9% from 2025 to 2030, reaching approximately US$1.49 billion by the end of that period. This growth stems from rising demands for accurate diagnostics and personalized medicine, particularly in response to the increasing prevalence of chronic diseases such as cancer. Advancements in technology, including automated dosimetry tools and AI integration, are enhancing precision and safety in treatment planning. The market's diagnostics segment retains the largest share, supported by the widespread use of PET and SPECT imaging. North America leads the market due to its advanced healthcare infrastructure and regulatory frameworks. Key players driving this market include GE Healthcare, Siemens Healthineers, and Philips.
Wed, 23 Jul 2025 14:01:00 GMT | PR Newswire